A Phase 1-2, Multicenter, Open-Label Study of the X- Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma and Follicular Lymphoma.
Phase of Trial: Phase I/II
Latest Information Update: 27 May 2011
At a glance
- Drugs AEG 35156 (Primary)
- Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Sponsors Aegera Therapeutics; Pharmascience
- 31 Jul 2008 Status change from planning to recruiting, according to an Aegera media release.
- 19 Jun 2008 New trial record.